Naples, Italy

Alessandro Fraldi




Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Napoli, IT (2015)
  • Naples, IT (2016)

Company Filing History:


Years Active: 2015-2016

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Alessandro Fraldi

Introduction

Alessandro Fraldi is a notable inventor based in Naples, Italy. He has made significant contributions to the field of gene therapy, particularly in the treatment of central nervous system (CNS) pathologies associated with mucopolysaccharidoses. With a total of two patents to his name, Fraldi's work is paving the way for new therapeutic strategies.

Latest Patents

Fraldi's latest patents focus on innovative therapeutic strategies to treat CNS pathology in mucopolysaccharidoses. The first patent provides nucleotide sequences encoding for a chimeric sulfatase, along with viral vectors that express these sequences for gene therapy. This invention has pharmaceutical applications for the chimeric expressed protein, particularly in the therapy of mucopolysaccharidosis type IIIA. The second patent mirrors the first, emphasizing the importance of these strategies in addressing CNS pathologies.

Career Highlights

Alessandro Fraldi is associated with Fondazione Telethon, an organization dedicated to funding research for genetic diseases. His work at this foundation has allowed him to focus on groundbreaking research that has the potential to change the lives of many patients suffering from rare genetic disorders.

Collaborations

Fraldi collaborates with Andrea Ballabio, a fellow researcher who shares his commitment to advancing gene therapy techniques. Their partnership has been instrumental in developing innovative solutions for treating complex genetic conditions.

Conclusion

Alessandro Fraldi's contributions to the field of gene therapy are significant and impactful. His patents and collaborative efforts are paving the way for new treatments that could greatly benefit patients with mucopolysaccharidoses.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…